Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q2 FY24 results · Jul–Sep 2023
Cohance Lifesciences reported revenue from operations of ₹231.05 crore (down 17.0% from Q2 FY23) and net profit of ₹79.56 crore (up 10.4% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 231.05 | 278.40 | −17.0% | 347.55 | −33.5% |
| Other income | 19.84 | 10.92 | +81.7% | 10.67 | +86.0% |
| Total income | 250.90 | 289.32 | −13.3% | 358.22 | −30.0% |
| Profit before tax | 105.41 | 98.48 | +7.0% | 163.94 | −35.7% |
| Net profit for the period | 79.56 | 72.06 | +10.4% | 120.59 | −34.0% |
| EPS, basic (₹) | 3.13 | 2.83 | +10.6% | 4.74 | −34.0% |
| Net margin (%) | 34.4 | 25.9 | 34.7 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 224.62 | 278.40 | −19.3% | 344.03 | −34.7% |
| Other income | 14.20 | 10.39 | +36.7% | 10.06 | +41.2% |
| Total income | 238.82 | 288.79 | −17.3% | 354.08 | −32.6% |
| Profit before tax | 100.57 | 105.99 | −5.1% | 167.65 | −40.0% |
| Net profit for the period | 74.73 | 78.92 | −5.3% | 124.29 | −39.9% |
| EPS, basic (₹) | 2.94 | 3.10 | −5.2% | 4.88 | −39.8% |
| Net margin (%) | 33.3 | 28.3 | 36.1 |
Consolidated
- Filed with BSE
- 13 Nov 2023, 16:32 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2023, 16:32 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE